EVR 6.7MSFT 0.21DAL -0.43JPM 1.28ATD.TO 0.245MTD 11.16CRWD -19.53
Eli Lilly & Co. (LLY)

NYSE:LLY

Eli Lilly & Co. (LLY)

1,125.27
+46.49 (4.31%)
as of Jun 4, 2026, 8:00:00 pm Market Open.
217 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 5, 2026, 12:00 am

This summary was created by AI, based on 28 opinions in the last 12 months.

Eli Lilly & Co. (LLY) continues to thrive in the competitive landscape of GLP-1 weight-loss drugs, exhibiting strong growth potential and an active pipeline that includes a promising oral formulation. Experts praise LLY for its effective management and ability to gain market share, especially against competitors like Novo Nordisk (NVO). Despite recent market fluctuations and concerns over valuation, many analysts see LLY as a resilient leader in the pharmaceutical sector with a robust growth outlook, projected earnings growth around 20%. However, there are varied opinions on the current valuation, with some suggesting it has become overvalued amid high PE ratios. The company's recent partnership with technology firms like Nvidia and its expansions into treating other health issues enhance its potential for future profitability, bolstering its position as a compelling long-term investment in the healthcare landscape.

consensus icon
Consensus
Bullish
valuation icon
Valuation
Overvalued
review icon
Similar
NVO
DON'T BUY

Eli Lilly & Co.(LLY)

Nov 02, 2011
This one is going nowhere fast. Declining earnings. Just had a big drug, Prexus, come off patent, which accounted for 11% of their sales. No new block busters on the horizon. Earnings consensus going from $4.30 to $3.60 next year.
Photo of Don LatoDon Lato
No
Unlock Rating
$37.48

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Jun 16, 2011
Industry could be considered a value trap. A large number of large scale pharmas are trading at depressed values because of US health reforms and patents expiring. However this one is in one of the better positions to see itself through this cycle. Have about 70 drugs, mainly in oncology, neuroscience and diabetes that they are working on in their pipeline.
Photo of Mohsin BashirMohsin BashirUnlock Rating
$37.22

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

May 12, 2010
In the same camp as many of the other big pharmas. Having trouble filling the pot. Patent expirations are taking revenue out. Good cash business with a good dividend of about 5.5%. A value trap.
Photo of Gordon ReidGordon ReidUnlock Rating
$34.78

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Mar 10, 2010
Similar to a lot of Pharma companies in that they have to find some growth. Will have patent expiries in 2011, which will create falling sales. Looks cheap and has a great dividend but it is a shrinking situation.
Photo of Gordon ReidGordon ReidUnlock Rating
$35.34

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Feb 18, 2010
2 issues that face phama stocks: one is health care and what will happen; and two is that the pipeline of fantastic drugs has slowed down. Treat it as a high dividend paying company and not look for huge increases in stock price.
Photo of Paul Harris, CFAPaul Harris, CFAUnlock Rating
$34.41

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Jun 16, 2009
All the pharmaceutical stocks are cheap. He would recommend Johnson & Johnson (JNJ-N) and Merck & Co. (MRK-N) ahead of this one. (See Top Picks.)
Photo of Charles BobrinskoyCharles Bobrinskoy
No
Unlock Rating
$32.98

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

May 07, 2009
Pharma is a sector that usually outperforms in times of crisis and in bear markets. They have generally been a good hiding spot. The group will probably lag any uptick in the market. 5.5% dividend.
Photo of Greg A. Taylor, CFA, BBAGreg A. Taylor, CFA, BBAUnlock Rating
$35.85

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Nov 07, 2006
One of the major concerns that pharmacy companies have is patent expiration and generics coming in. Doesn't think they have any major products coming off patents until 2010.
Photo of Ian NakamotoIan Nakamoto
Owned
Unlock Rating
$56.98

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Oct 31, 2006
Hasn't gone anywhere because it hasn't any blockbuster drugs. Has a good pipeline. Demographically, diabetes is set to explode.
Photo of Norman LevineNorman LevineUnlock Rating
$56.01

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Eli Lilly & Co.(LLY)

Mar 15, 2006
Eli Lilly is a good company. It looks fine. It has come down with the other large cap drug stocks in the States. Need to be patient. It offers decent value here.
Photo of Laura WallaceLaura Wallace
No
Unlock Rating
$56.97

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Aug 25, 2005
This is a part of the market that's lagging. There has been such a slowdown in the growth rates.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$53.50

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Jul 13, 2005
Prefers others such as Abbott Labs (ABT-N).
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$56.37

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Eli Lilly & Co.(LLY)

May 03, 2005
Pharmaceutical sector did very poorly over the last 2 years, but deceleration in revenue growth has slowed and profitability has started to improve. Look for the strongest perfoming stock in the sector. As Eli Lilly (LLY-N) is performing better, that would be the better of the 2, but would suggest you look at Sanofi-Aventis (SNY-N) which is close to new highs and Teva Pharmaceuticals (TEVA-Q) in generics.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$59.75

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Mar 15, 2005
A little bit of risk in a 3/6 month view as to whether they can retain their patent on Sprizecta (?), but the longer term they have the best drug pipeline and growth in the sector. OK for a long term hold.
Photo of George LougheryGeorge LougheryUnlock Rating
$52.70

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Eli Lilly & Co.(LLY)

Aug 13, 2004
Lots of new products. Rapid profit growth.
Photo of Samuel D. IsalySamuel D. Isaly
Owned
Unlock Rating
$61.57

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
Showing 181 to 195 of 202 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

RY.TO -0.77$270.17
BHP -2.07$88.78
TA.TO -2.08$18
V 2.68$322.86
TOU.TO -1.22$64.2

Today's Top Picks

EVR 6.7$346.79
MSFT 0.21$428.26
DAL -0.43$79.08
JPM 1.28$312.17
ATD.TO 0.245$81.035

Popular Articles

Latest Sell Signals

PRL.TO 0.15$21.35
CNQ.TO -0.42$65.8
SHOP.TO -0.66$160.88
RIO -2.46$105.4
BB.TO -0.95$13.45

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica